Catalyst Pharmaceuticals에 대한 매도 수량은 투자자에게 Catalyst Pharmaceuticals의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Catalyst Pharmaceuticals (NASDAQ:CPRX) 주식, 공매도 수량 보고

CATALYST PHARMACEUTICALS INC

Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).

Lucid EV. Photo by Around the World Photos on Shutterstock

Equities

Mid Cap

News

Movers

Tech

ARQT

CELH

CPRX

DGNX

GLNG

LCID

SBSW

STNE

지난 일주일 동안 가장 실적이 좋았던 중형주 10개 종목은 다음과 같다. 디지넥스, 넥스트데케이드, 셀시우스, 시그넷 주얼러스, 뉴 포트리스, 밀로즈, 아커티스, 루시드, 캐털리스트, 스톤코

셀시우스·루시드·시그넷 등 지난주 급등한 중형주 10종목 (3월 17일~21일)

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals Inc

These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Diginex Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) shares surged 108.29%, probably amid an overall rebound after investor uncertainty and several risk factors that led to markets entering correction territory last week.</li>
<li>NextDecade Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXT#NASDAQ">NEXT</a>) shares escalated 25.07%. The company announced that the U.S. Court of Appeals for the D.C. Circuit Court issued a revision to the August 2024 judgment, removing vacatur risk on the Federal Energy Regulatory Commission&#8217;s order.</li>
<li>Celsius Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) stock upped 21.60%, likely reacting to news that PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) is acquiring prebiotic<a href="https://www.benzinga.com//node/44360669" target="_blank" rel="noreferrer noopener"> soda brand Poppi for $1.95 billion</a>.</li>
<li>Signet Jewelers Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) stock jumped 21.08% after it reported fourth-quarter FY25 earnings results. Several analysts <a href="https://www.benzinga.com//node/44423649" target="_blank" rel="noreferrer noopener">revised the stock&#8217;s price forecast</a>.</li>
<li>New Fortress Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) shares escalated 20.63% amid weakness in the dollar after the U.S. launched strikes on Houthi targets. Additionally, strong Chinese economic data could be lifting the demand outlook.</li>
<li>Millrose Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRP#NYSE">MRP</a>) shares jumped 16.61% after the company declared its inaugural dividend <a href="https://www.benzinga.com//node/44365712" target="_blank" rel="noreferrer noopener">and issued a 2025 outlook</a>.</li>
<li>Arcutis Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) stock gained 16.35% last week after Health Canada approved its Zoryve cream for treating mild to moderate atopic dermatitis.</li>
<li>Lucid Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) stock increased 15.79% after Morgan Stanley upgraded the stock <a href="https://www.benzinga.com//node/44373086" target="_blank" rel="noreferrer noopener">from Underweight to Equal-Weight</a>.</li>
<li>Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) stock upped 15.27%.</li>
<li>StoneCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) shares were up 14.20% after the company reported better-than-expected <a href="https://www.benzinga.com//node/44384778" target="_blank" rel="noreferrer noopener">fourth-quarter EPS and sales</a>.</li>
</ol>
Photo by Around the World Photos on Shutterstock
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44450329/robinhood-roku-and-shopify-are-among-top-10-large-cap-gainers-last-week-mar-17-mar-21-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Robinhood, Roku And Shopify Are Among Top 10 Large-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44450375/xpeng-reddit-and-nucor-are-among-top-10-large-cap-losers-last-week-mar-17-mar-21-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">XPeng, Reddit And Micron Tech Are Among Top 10 Large-Cap Losers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?</a></li>
</ul>

Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?

Baird analyst Joel Beatty maintains Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Outperform and raises the price target from $28 to $32.

Price Target

Analyst Ratings

Baird Maintains Outperform on Catalyst Pharmaceuticals, Raises Price Target to $32

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy and maintains $35 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Catalyst Pharmaceuticals, Maintains $35 Price Target

Across the recent three months, 4 analysts have shared their insights on Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $31.5, a high estimate of $35.00, and a low estimate of $28.00. Witnessing a positive shift, the current average has risen by 1.61% from the previous average price target of $31.00.
<img src="https://www.benzinga.com/files/images/story/2025/1740679219_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Catalyst Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$33.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$28.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Catalyst Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Catalyst Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Catalyst Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Catalyst Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CPRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Catalyst Pharmaceuticals analyst ratings.</a>
<h2>About Catalyst Pharmaceuticals</h2>
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
<h3>Catalyst Pharmaceuticals: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Catalyst Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 25.33% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Catalyst Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of 34.1%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.91%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Catalyst Pharmaceuticals's ROA stands out, surpassing industry averages. With an impressive ROA of 5.94%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Catalyst Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Catalyst Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Stephens &amp; Co. analyst Sudan Loganathan reiterates Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Overweight and maintains $33 price target.

Stephens & Co. Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $33 Price Target

WIIM

Catalyst Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results.

Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.34 by 105.88 percent. This is a 32.08 percent increase over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $141.81 million which beat the analyst consensus estimate of $134.20 million by 5.67 percent. This is a 28.26 percent increase over sales of $110.57 million the same period last year.

Earnings

Earnings Beats

Catalyst Pharmaceuticals Q4 2024 Adj EPS $0.70 Beats $0.34 Estimate, Sales $141.81M Beat $134.20M Estimate

AAOI

ABEV

ACAD

ACMR

ADTN

ALEC

AMBA

AMBC

AMSF

ARDT

ARHS

ARIS

ARKO

ASTE

ATEC

AVDX

AVNS

BATRA

BATRK

BBSI

BLMN

BXSL

BYND

CAPL

CDNA

CERT

CLDT

CLPT

COCO

COMM

CORT

Core Scientific, Inc. - Class A Common Stock

CORZ

CRGY

CSAN

CTRI

DHIL

DMRC

DOLE

DORM

EBAY

ECPG

EHTH

ENIC

ENOV

ERII

ESCA

ESTA

EVTC

FTAI

FWRD

GERN

GOGL

GSX Techedu Inc. American Depositary Shares

GOTU

GRBK

HCAT

HNST

IBTA

IMCR

Earnings Scheduled For February 26, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Joel Beatty initiated coverage on Catalyst Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with an Outperform rating and announced a price target of $28. Catalyst Pharmaceuticals shares closed at $22.62 on Monday. <a href="https://www.benzinga.com/quote/CPRX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst John Freeman initiated coverage on Expand Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Strong Buy rating and announced a price target of $135. Expand Energy shares closed at $102.87 on Monday. <a href="https://www.benzinga.com/quote/EXE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst John Kim initiated coverage on Terreno Realty Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRNO#NYSE">TRNO</a>) with a Market Perform rating and announced a price target of $71. Terreno Realty shares closed at $65.26 on Monday. <a href="https://www.benzinga.com/quote/TRNO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Andy Chen initiated coverage on Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with an Outperform rating and announced a price target of $49. Vera Therapeutics shares closed at $36.54 on Monday. <a href="https://www.benzinga.com/quote/VERA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Andy Chen initiated coverage on Oruka Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKA#NASDAQ">ORKA</a>) with an Outperform rating and announced a price target of $20. Oruka Therapeutics shares closed at $13.70 on Monday. <a href="https://www.benzinga.com/quote/ORKA/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock.</a></li>
</ul>
Considering buying EXE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-1024x593.png" alt="" class="wp-image-764898" style="width:551px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24.png 1110w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Initiation

Pre-Market Outlook

Markets

Trading Ideas

ORKA

TRNO

VERA

This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Analysts' ratings for Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Catalyst Pharmaceuticals, revealing an average target of $32.33, a high estimate of $36.00, and a low estimate of $28.00. This upward trend is evident, with the current average reflecting a 7.77% increase from the previous average price target of $30.00.
<img src="https://www.benzinga.com/files/images/story/2025/1738670427_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Catalyst Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$28.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$36.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Catalyst Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Catalyst Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Catalyst Pharmaceuticals's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Catalyst Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CPRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Catalyst Pharmaceuticals analyst ratings.</a>
<h2>Discovering Catalyst Pharmaceuticals: A Closer Look</h2>
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
<h3>Catalyst Pharmaceuticals: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Catalyst Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 25.33% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Catalyst Pharmaceuticals's net margin excels beyond industry benchmarks, reaching 34.1%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.91%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Catalyst Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 5.94%. This signifies efficient management of assets and strong financial health.
Debt Management: Catalyst Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 6 Analysts Discuss Catalyst Pharmaceuticals Stock

Baird analyst Joel Beatty initiates coverage on Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Outperform rating and announces Price Target of $28.

Baird Initiates Coverage On Catalyst Pharmaceuticals with Outperform Rating, Announces Price Target of $28

Biotech

General

Catalyst Pharmaceuticals Reported That Its Sub-Licensee In Japan, Dydo Pharma, Has Launched Firdapse (Amifampridine) Tablets 10MG In Japan For The Indication Of Improving Muscle Weakness In Patients Living With Lambert-Eaton Myasthenic Syndrome

HC Wainwright &amp; Co. analyst Andrew Fein maintains Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy and raises the price target from $30 to $35.

HC Wainwright & Co. Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $35

B of A Securities analyst Jason Gerberry reiterates Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy and maintains $30 price target.

B of A Securities Reiterates Buy on Catalyst Pharmaceuticals, Maintains $30 Price Target

On Wednesday, Catalyst Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>).
This Agreement resolves the patent litigation brought by Catalyst and its licensor SERB S.A in response to Teva&#8217;s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Firdapse (amifampridine) 10 mg tablets before the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42881700/catalyst-pharmaceuticals-announces-settlement-of-firdapse-amifampridine-patent-litigation-with-tev" rel="noreferrer noopener">expiration of the applicable patents</a>.
If approved by the FDA, Teva will not market its generic version of Firdapse in the United States before February 25, 2035, unless certain limited circumstances customarily included in these types of agreements occur.
The parties will terminate all ongoing patent litigation between Catalyst/SERB and Teva regarding Firdapse patents pending in the U.S. District Court for the District of New Jersey.
The ongoing Firdapse patent litigation involves two defendants: Hetero, which is being challenged on all of Firdapse&#8217;s Orange Book-listed patents, and Lupin, which is facing a case focused on Catalyst&#8217;s Firdapse patent that expires in 2037.
In the Notice Letter in January 2023, Teva stated that it intended to market a generic version of Firdapse before the expiration of multiple of Catalyst&#8217;s patents listed in the <a target="_blank" href="https://www.benzinga.com/news/23/01/30523209/why-catalyst-pharmaceuticals-shares-are-moving" rel="noreferrer noopener">FDA Orange Book</a>.
In May, the FDA approved its supplemental New Drug Application, increasing the indicated maximum daily dose of Firdapse&#8217;s (amifampridine) for adults and pediatric patients weighing more than 45 kg from 80 mg to 100 mg for Lambert-Eaton myasthenic syndrome (LEMS).
LEMS is a rare autoimmune disorder characterized by muscle weakness and fatigue. Firdapse is a potassium channel blocker indicated for LEMS in adults and pediatric patients six years of age and older and works by increasing the release of acetylcholine, a neurotransmitter, at the neuromuscular junction, which helps improve muscle <a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/g39094213/catalyst-pharmaceuticals-receives-u-s-fda-approval-for-increased-maximum-daily-dose-for-firdapse" rel="noreferrer noopener">function in people with LEMS</a>.
In the third quarter of 2024, Firdapse revenues increased 19.7% year over year to $79.3&nbsp;million. The company expects full-year 2024 net product revenue of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41787062/catalyst-pharmaceuticals-reports-strong-third-quarter-2024-financial-results-and-provides-corporat" rel="noreferrer noopener">$300 million—$310 million</a>.
Price Action: CPRX stock closed at $19.53 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/asset-sales/25/01/42896830/clear-channel-outdoor-plans-375-million-debt-repayment-following-625-million-sale-of-european-operations" target="_blank" rel="noreferrer noopener">Clear Channel Outdoor Plans $375 Million Debt Repayment Following $625 Million Sale of European Operations</a></li>
</ul>

Large Cap

Health Care

Legal

TEVA

Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical

Trading Halt: Halt status updated at 12:55:00 PM ET: Quotation Resumption: News and Resumption Times

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licensor SERB S.A. ("SERB") have entered into a Settlement Agreement (Agreement) with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. (collectively Teva). This Agreement resolves the patent litigation brought by Catalyst and SERB in response to Teva's Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of FIRDAPSE&#xAE; (amifampridine) 10 mg tablets prior to expiration of the applicable patents.
Pursuant to the terms of the Agreement, Teva will not market its generic version of FIRDAPSE in the United States any earlier than February 25, 2035, if approved by the U.S. Food and Drug Administration (FDA), unless certain limited circumstances customarily included in these types of agreements occur. In accordance with the Agreement, the parties will terminate all ongoing patent litigation between Catalyst/SERB and Teva regarding FIRDAPSE patents pending in the U.S. District Court for the District of New Jersey. The pending FIRDAPSE patent litigation against the remaining defendants, Hetero (for all of FIRDAPSE's Orange Book-listed patents) and Lupin (only for Catalyst's FIRDAPSE patent expiring in 2037), is ongoing.
As required by law, the companies will submit the confidential license agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review.
 &nbsp;

Contracts

Catalyst Pharmaceuticals Announces Settlement Of FIRDAPSE Patent Litigation With Teva Pharmaceuticals; Teva Will Not Market Its Generic Version Of FIRDAPSE In The U.S. Any Earlier Than February 25, 2035, If Approved By The FDA

Trading Halt: Halted at 12:25:07 p.m. ET - Trading Halt: Halt News Pending

Disclosed on November 21, Patrick J McEnany, Director at Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>), executed a substantial insider sell as per the latest SEC filing.
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001369568/000116169724000457//Archives/edgar/data/1369568/000116169724000457/0001161697-24-000457-index.htm">U.S. Securities and Exchange Commission</a> on Thursday, McEnany sold 170,845 shares of Catalyst Pharmaceuticals. The total transaction value is $3,627,258.
Monitoring the market, Catalyst Pharmaceuticals's shares up by 1.23% at $21.38 during Friday's morning.
<h3>Discovering Catalyst Pharmaceuticals: A Closer Look</h3>
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
<h3>Breaking Down Catalyst Pharmaceuticals's Financial Performance</h3>
Revenue Growth: Over the 3 months period, Catalyst Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 25.33% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 85.02%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Catalyst Pharmaceuticals's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 0.37.
</li>
</ul>
Debt Management: Catalyst Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.0, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Catalyst Pharmaceuticals's P/E ratio of 17.9 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 5.59 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 9.84, Catalyst Pharmaceuticals presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Breaking Down the Significance of Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001369568">Check Out The Full List Of Catalyst Pharmaceuticals's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Catalyst Pharmaceuticals Insider Trades Send A Signal

Press Releases

Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List

Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference

Comments

Catalyst Pharmaceuticals

매도 수량

Catalyst Pharmaceuticals (NASDAQ:CPRX) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌